References of "Cavalier, Etienne"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailSkeletal health in breast cancer survivors
Bruyère, Olivier ULiege; Bergmann, Pierre; CAVALIER, Etienne ULiege et al

in Maturitas (2017), (In press),

Although some risk factors for breast cancer might be protective for osteoporosis, several cross-sectional studies have reported, nevertheless, that patients with breast cancer have a lower bone mass and ... [more ▼]

Although some risk factors for breast cancer might be protective for osteoporosis, several cross-sectional studies have reported, nevertheless, that patients with breast cancer have a lower bone mass and potentially a higher incidence of fractures than expected. In any case, it appears that patients with breast cancer are not protected from osteoporosis, which provides further support for the recommendation that bone health is assessed after a diagnosis of breast cancer. Most adjuvant therapies will lead to increased bone loss and a higher fracture rate. Among the adjuvant therapy options for premenopausal patients with breast cancer, endocrine therapy (ovarian suppression) and chemotherapy can result in cancer treatment-induced bone loss (CTIBL) of up to 10% at the lumbar spine after one year. Antiresorptive therapies prevent CTIBL in premenopausal women with breast cancer. Most of the evidence demonstrating the efficacy of bisphosphonates in the prevention of CTIBL is derived from clinical trials with zoledronic acid. The addition of zoledronic acid 4 mg per six months to adjuvant endocrine therapy maintained and even increased bone mass during a 3-year treatment period and significantly improved disease-free survival in a population of young women who underwent menopause due to the adjuvant treatment. The major contributor to bone loss in the adjuvant treatment of breast cancer in postmenopausal women is the use of aromatase inhibitors (AIs). Oncology trials have underestimated the fracture risk in the setting of AI-induced bone loss. In the ABCSG-18 study, the only trial in which fracture incidence was the primary endpoint, the rate of clinical fractures was close to 10% after 3 years in the placebo group on AIs only. Bisphosphonates and denosumab at osteoporosis treatment doses can counteract AI-induced bone loss. In the ABCSG-18 trial, treatment with denosumab 60 mg injection every 6 months reduced the risk of first clinical fracture relative to placebo by 50%. Current guidelines recommend antiresorptive therapy in patients with a baseline T score of<−2.0 or with two or more clinical risk factors for fracture. These recent guidelines will need to be updated, as similar significant protective effects were seen in women with either normal or low bone mass. Moreover, a formal meta-analysis of individual patient data from more than 18,000 women in 26 randomized trials of adjuvant zoledronic acid or clodronate treatment for early breast cancer revealed that bisphosphonates significantly reduced the risk of first distant recurrence in bone and the risk of breast cancer mortality, at least in postmenopausal women. Even though the increased risk of fracture during adjuvant treatment for breast cancer in postmenopausal women is notable, an enhanced risk of fracture in long-term survivors of breast cancer remains under debate. The most recent studies suggest that Caucasian breast cancer survivors do not have a significantly increased risk of osteoporotic fracture over the long term. [less ▲]

Detailed reference viewed: 17 (3 ULiège)
Full Text
Peer Reviewed
See detailOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.
Gielen, E.; Bergmann, P.; Bruyère, Olivier ULiege et al

in Calcified Tissue International (2017), 101(2), 111-31

In this consensus paper, the Belgian Bone Club aims to provide a state of the art on the epidemiology, diagnosis, and management of osteoporosis in frail individuals, including patients with anorexia ... [more ▼]

In this consensus paper, the Belgian Bone Club aims to provide a state of the art on the epidemiology, diagnosis, and management of osteoporosis in frail individuals, including patients with anorexia nervosa, patients on dialysis, cancer patients, persons with sarcopenia, and the oldest old. All these conditions may indeed induce bone loss that is superimposed on physiological bone loss and often remains under-recognized and under-treated. This is of particular concern because of the major burden of osteoporotic fractures in terms of morbidity, mortality, and economic cost. Therefore, there is an urgent need to appreciate bone loss associated with these conditions, as this may improve diagnosis and management of bone loss and fracture risk in clinical practice. [less ▲]

Detailed reference viewed: 26 (13 ULiège)
Full Text
Peer Reviewed
See detailImpact of the type of dialysis membranes on the circulating concentration of markers of vitamin D metabolism.
Cavalier, Etienne ULiege; Torres, Pablo U.; Dubois, Bernard E. et al

in International Journal of Artificial Organs (2017)

INTRODUCTION: Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend vitamin D supplementation in hemodialyzed patients to monitor 25(OH)-vitamin D 25(OH)D levels. However, patient-to ... [more ▼]

INTRODUCTION: Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend vitamin D supplementation in hemodialyzed patients to monitor 25(OH)-vitamin D 25(OH)D levels. However, patient-to-patient inconsistency can be observed in response to the treatment. In this study, we aimed to evaluate the impact of the dialysis membrane on 25(OH)D, albumin (Alb) and vitamin D-binding protein (VDBP), the major players of vitamin D transport and storage. MATERIAL AND METHODS: Alb (Cobas), VDBP (R&D) and 25(OH)D (liquid chromatography-tandem mass spectrometry) were measured in 75 patients before and after a 4-hour dialysis session. Ten dialysis membranes were used: FX10, FX80, FX800, BK-2.1F, BG-2.1U, Rexeed 15 A, Rexeed 21 A, TS 1.8 SL and TS 2.1 SL manque la ELISIO 21H. Accordingly, 13 patients were dialyzed with membranes possessing high adsorption and high cut-off properties (BK), 17 with membranes possessing high adsorption but usual cut-off properties (BG) and all the remaining 45 patients with polysufone (PS) membranes with usual adsorptive and cut-off properties. Among these 45 patients treated with PS, we compared those treated by classical dialysis (HD) (n = 14) and hemodiafiltration (HDF) (n = 31). Results were corrected for total extracellular volume to take into consideration the hemoconcentration after dialysis. RESULTS: The 3 analytes showed a decreased concentration after the dialysis session. The decrease of ALB, VDBP and 25(OH)D was similar with the adsorptive (BG) and PS membranes. However, patients treated with adsorptive and high cut-off membrane (BK) presented a significantly higher decrease values of Alb (-9.6%[-15.1; -7.5]), of VDBP (-20.6%[-36.6; -17.2] and 25(OH)D (-17%[-27.3; -12.3]) compared to other membranes (BG and PS).When we limited our study to PS membranes, we did not observe any significant difference between the HD or HDF modalities in the decrease for any of the studied parameters. CONCLUSIONS: A significant loss of Alb, VDBP and 25(OH)D occurs after a dialysis session. This loss is significantly more important when patients are dialyzed with high adsorption and high cut-off dialysis membranes. [less ▲]

Detailed reference viewed: 15 (4 ULiège)
Full Text
Peer Reviewed
See detailIntérêt de nouveaux marqueurs biologiques dans l’évaluation de la sarcopénie en dialyse.
DELANAYE, Pierre ULiege; QUINONEZ, Kevin ULiege; Buckinx, Fanny ULiege et al

in Néphrologie & Thérapeutique (2017), 13(5), 269

Detailed reference viewed: 19 (2 ULiège)
Full Text
Peer Reviewed
See detailAssociation entre les taux circulants de matrix-gla protein et rigidité artérielle en transplantation rénale.
Dinic, M; Maillard, N; DELANAYE, Pierre ULiege et al

in Néphrologie & Thérapeutique (2017), 13(5), 309

Detailed reference viewed: 19 (4 ULiège)
Full Text
Peer Reviewed
See detailMeasuring Plasma Clearance for Exact Assessment of GFR: Multi versus Single Sampling
Ebert, Natalie; Schaeffner, Elke; Pottel, Hans et al

Poster (2017)

Detailed reference viewed: 30 (1 ULiège)
Full Text
Peer Reviewed
See detailVitamin D and osteosarcopenia: an update from epidemiological studies.
Bruyère, Olivier ULiege; CAVALIER, Etienne ULiege; Reginster, Jean-Yves ULiege

in Current Opinion in Clinical Nutrition & Metabolic Care (2017), 20(6),

PURPOSE OF REVIEW: The review summarizes recent epidemiological studies that examined the relationship between osteoporosis and sarcopenia to assess the impact of vitamin D status or supplementation on ... [more ▼]

PURPOSE OF REVIEW: The review summarizes recent epidemiological studies that examined the relationship between osteoporosis and sarcopenia to assess the impact of vitamin D status or supplementation on health outcomes related to these two medical conditions. [less ▲]

Detailed reference viewed: 34 (12 ULiège)
Full Text
Peer Reviewed
See detailLes pentes d’évolution des CTX, de la phosphatase alkaline osseuse et du P1NP sont associées à celles de la PTH en hémodialyse chronique.
Maillard, Nicolas; Warling, Xavier; Moonen, Martial et al

Poster (2017)

Detailed reference viewed: 26 (2 ULiège)
Full Text
Peer Reviewed
See detailDFG en population saine africaine : comparaison des performances de 11 équations d’estimation à marquer unique ou combinés, avec et sans facteur ethnique
yayo, Eric; Yao-Papo, E; Gnionsahé, A et al

in Néphrologie & Thérapeutique (2017), 13(5), 277

Detailed reference viewed: 24 (1 ULiège)
Full Text
Peer Reviewed
See detailVariations of parathyroid hormone and bone biomarkers are concordant only after a long term follow-up in hemodialyzed patients
DELANAYE, Pierre ULiege; Warling, Xavier; Moonen, Martial et al

in Scientific Reports (2017), 7(1), 12623

Detailed reference viewed: 20 (4 ULiège)
Full Text
Peer Reviewed
See detailOccurrence of Clinical Bone Fracture Following a Prolonged Stay in Intensive Care Unit: A Retrospective Controlled Study
ROUSSEAU, Anne-Françoise ULiege; CAVALIER, Etienne ULiege; Reginster, Jean-Yves ULiege et al

in Calcified Tissue International (2017), (Online),

Clinical consequences of critical illness and critical care (CC) on bone health remain largely unexplored. This retrospective study aimed to assess the number of new bone fractures (BF) following a ... [more ▼]

Clinical consequences of critical illness and critical care (CC) on bone health remain largely unexplored. This retrospective study aimed to assess the number of new bone fractures (BF) following a prolonged length of stay (LOS) in intensive care unit (ICU). Adults admitted in our tertiary ICU during 2013 with a stay [7 days were included (CC group). Patients who died in ICU or lost to follow-up were excluded. For each CC patient still alive after 2 years of follow-up, 2 control patients, scheduled for surgery during 2013, were recruited and matched for gender and age. Basal fracture risk before admission was calculated using FRAX tool. General practitioners were phoned to check out new bone fracture (BF) during 2 years after admission. Of the 457 enrolled CC patients, 207 did not meet inclusion criteria and 72 died during FU (median age 72 [65–77] years). New BF occurred in 9 of the 178 patients still alive at the end of FU (5%). Median age of these patients was 64 [53–73] years. Fractured patients did not differ from non-fractured ones based on demographic and clinical characteristics, excepting for FRAX risks that were higher in fractured patients. In the control group, 327 patients were analyzed. Their rate of BF was 3.4% without statistical significance compared to the CC group. FRAX risks were similar in both groups. The risk of new BF in CC group, expressed as an odds ratio, was 50% higher than in the control group without achieving statistical significance (odds ratio 1.53; 95% confidence interval 0.62–3.77; p = 0.35). When comparing ICU survivors to patients who underwent uncomplicated surgery in the present preliminary study included limited cohorts, the fracture risk in the 2 years following prolonged ICU stay was not statistically higher. However, CC fractured patients had higher FRAX risks than non-fractured patients. Such screening could help to target prevention and appropriate treatment strategies. [less ▲]

Detailed reference viewed: 31 (11 ULiège)
Full Text
Peer Reviewed
See detailMulticenter Evaluation of Cystatin C Measurement after Assay Standardization.
Bargnoux, Anne-Sophie; Pieroni, Laurence; Cristol, Jean-Paul et al

in Clinical Chemistry (2017), 63(4), 833-841

BACKGROUND: Since 2010, a certified reference material ERM-DA471/IFCC has been available for cystatin C (CysC). This study aimed to assess the sources of uncertainty in results for clinical samples ... [more ▼]

BACKGROUND: Since 2010, a certified reference material ERM-DA471/IFCC has been available for cystatin C (CysC). This study aimed to assess the sources of uncertainty in results for clinical samples measured using standardized assays. METHODS: This evaluation was performed in 2015 and involved 7 clinical laboratories located in France and Belgium. CysC was measured in a panel of 4 serum pools using 8 automated assays and a candidate isotope dilution mass spectrometry reference measurement procedure. Sources of uncertainty (imprecision and bias) were evaluated to calculate the relative expanded combined uncertainty for each CysC assay. Uncertainty was judged against the performance specifications derived from the biological variation model. RESULTS: Only Siemens reagents on the Siemens systems and, to a lesser extent, DiaSys reagents on the Cobas system, provided results that met the minimum performance criterion calculated according to the intraindividual and interindividual biological variations. Although the imprecision was acceptable for almost all assays, an increase in the bias with concentration was observed for Gentian reagents, and unacceptably high biases were observed for Abbott and Roche reagents on their own systems. CONCLUSIONS: This comprehensive picture of the market situation since the release of ERM-DA471/IFCC shows that bias remains the major component of the combined uncertainty because of possible problems associated with the implementation of traceability. Although some manufacturers have clearly improved their calibration protocols relative to ERM-DA471, most of them failed to meet the criteria for acceptable CysC measurements. [less ▲]

Detailed reference viewed: 19 (2 ULiège)
Full Text
Peer Reviewed
See detailSerum Creatinine: Not So Simple!
DELANAYE, Pierre ULiege; Cavalier, Etienne ULiege; Pottel, Hans

in Nephron (2017), 136(4), 302-308

Measuring serum creatinine is cheap and commonly done in daily practice. However, interpretation of serum creatinine results is not always easy. In this review, we will briefly remind the physiological ... [more ▼]

Measuring serum creatinine is cheap and commonly done in daily practice. However, interpretation of serum creatinine results is not always easy. In this review, we will briefly remind the physiological limitations of serum creatinine due notably to its tubular secretion and the influence of muscular mass or protein intake on its concentration. We mainly focus on the analytical limitations of serum creatinine, insisting on important concept such as reference intervals, standardization (and IDMS traceability), analytical interferences, analytical coefficient of variation (CV), biological CV and critical difference. Because the relationship between serum creatinine and glomerular filtration rate is hyperbolic, all these CVs will impact not only the precision of serum creatinine but still more the precision of different creatinine-based equations, especially in low or normal-low creatinine levels (or high or normal-high glomerular filtration rate range). [less ▲]

Detailed reference viewed: 25 (2 ULiège)
Full Text
Peer Reviewed
See detailBiomarkers Predicting Bone Turnover in the Setting of CKD.
Evenepoel, Pieter; Cavalier, Etienne ULiege; D'Haese, Patrick C.

in Current Osteoporosis Reports (2017)

PURPOSE OF THE REVIEW: Impaired bone quality contributes to the increased fracture risk in chronic kidney disease patients. Both low and high turnover bone disease may compromise bone quality. The ... [more ▼]

PURPOSE OF THE REVIEW: Impaired bone quality contributes to the increased fracture risk in chronic kidney disease patients. Both low and high turnover bone disease may compromise bone quality. The question arises whether bone biomarkers may be additive or replace bone histormorphometry for diagnosing the extremes of bone turnover. RECENT FINDINGS: Studies exploring the performance of established and emerging bone biomarkers against histomorphometric assessment of bone turnover are limited and overall yield inconclusive results as to their diagnostic utility. Bone biomarkers, although promising, currently fail to meet the needed diagnostic accuracy to replace bone histomorphometry and thus are not yet ready for clinical use. Bone biomarkers have not only several advantages, but also important limitations such as high biological variability, retention with kidney disease, preanalytical issues, and interassay variability. These important issues must be considered when developing and evaluating bone biomarkers. There is an urgent need for harmonization and standardization of available assays and additional bone biopsy studies. [less ▲]

Detailed reference viewed: 10 (1 ULiège)
Full Text
Peer Reviewed
See detailDistinction between urine crystals by automated urine analyzer SediMAX conTRUST is specific but lacks of sensitivity.
Castiglione, Vincent ULiege; CAVALIER, Etienne ULiege; Diop, Coumba Souley ULiege et al

in Clinical Chemistry & Laboratory Medicine (2017)

Urine crystals are commonly encountered but few papers have been published about it while it is useful for patient’s follow-up, particularly the stone-formers. For the first time to our knowledge, we have ... [more ▼]

Urine crystals are commonly encountered but few papers have been published about it while it is useful for patient’s follow-up, particularly the stone-formers. For the first time to our knowledge, we have assessed the performance of an automated urine analyzer to identify and distinguish several types of crystals in a very large cohort of samples. We share in this report the results of method comparison of the SediMAX conTRUST with the polarized light microscopy which is the gold standard. We showed that the distinction between crystals and other urine elements was accurate. Negative predictive value was very good, but the positive predictive value was poor for most of crystals. The discrimination of different types of crystals between them by the automated urine analyzer still requires improvement to decrease reviewing rate and help clinician. [less ▲]

Detailed reference viewed: 35 (5 ULiège)
Full Text
Peer Reviewed
See detailVitamin K plasma levels determination in human health
Fusaro, M; Gallieni, M; Rizzo, MA et al

in Clinical Chemistry & Laboratory Medicine (2017), 55(6), 789-799

Detailed reference viewed: 14 (4 ULiège)
Full Text
Peer Reviewed
See detailWhen obtaining a blood sample from the right arm was not the right thing to do: a case of elevated parathyroid hormone levels 27 years after thyroidectomy.
Wolff, Fleur; Gervy, Christine; Cavalier, Etienne ULiege et al

in Clinical Chemistry & Laboratory Medicine (2016)

Detailed reference viewed: 21 (1 ULiège)
Full Text
Peer Reviewed
See detailAssociation entre taux circulants de matrix-gla protéine et rigidité artérielle en transplantation rénale.
Dinic, Miriana; Maillard, Nicolas; DELANAYE, Pierre ULiege et al

Conference (2016, December)

Detailed reference viewed: 15 (8 ULiège)